CYDY - CytoDyn advances leronlimab into Phase 2 stage in breast cancer trial

MicroStockHub/iStock via Getty Images CytoDyn (CYDY) says that its clinical development of leronlimab in combination with chemotherapy, carboplatin for the treatment of metastatic triple-negative breast cancer (mTNBC) has progressed from Phase 1b stage to a Phase 2 trial. Leronlimab, a CCR5 antagonist, will now be administered with a 700 mg dose in mTNBC trial and another “Basket” trial for 22 patients with solid tumor cancers, “as well as compassionate use, eIND and “right-to-try” patients,” CytoDyn said in the statement. Preliminary efficacy data from the responders of mTNBC are expected in about two weeks. The FDA has granted the Fast Track designation for leronlimab in mTNBC. In January, CytoDyn announced encouraging data for leronlimab in its clinical trials for mTNBC and metastatic breast cancer ((MBC)).

For further details see:

CytoDyn advances leronlimab into Phase 2 stage in breast cancer trial